

Contents

Contributors	<i>xvii</i>
Preface	<i>xxi</i>
Acknowledgements	<i>xxv</i>

Part I Introduction to Pharmacoepidemiology 1

1 What is Pharmacoepidemiology? 3

Brian L. Strom

Introduction 3

Definition of Pharmacoepidemiology 3

Pharmacoepidemiology Versus Clinical Pharmacology 4

Pharmacoepidemiology Versus Epidemiology 5

Historical Background 5

Early Legislation 5

Drug Crises and Resulting Regulatory Actions 7

Legislative Actions Resulting from Drug Crises 9

Intellectual Development of Pharmacoepidemiology Emerging from Drug Crises 10

The Current Drug Approval Process 13

Drug Approval in the US 13

Drug Approval in Other Countries 14

Potential Contributions of Pharmacoepidemiology 15

Supplementary Information 16

New Types of Information Not Available from Premarketing Studies 17

General Contributions of Pharmacoepidemiology 17

Key Points 18

Further Reading 18

2 Study Designs Available for Pharmacoepidemiologic Studies 20

Brian L. Strom

Introduction 20

Overview of the Scientific Method 20

Types of Errors that one Can Make in Performing a Study 22

Criteria for the Causal Nature of an Association 23

Epidemiologic Study Designs 26

Case Reports 26

Case Series 26

Analyses of Secular Trends	27
Case–Control Studies	28
Cohort Studies	28
Analysis of Case–Control and Cohort Studies	29
Randomized Clinical Trials	30
Discussion	31
Conclusion	32
Key Points	32
Further Reading	33
3 Sample Size Considerations for Pharmacoepidemiologic Studies	35
<i>Brian L. Strom</i>	
Introduction	35
Sample Size Calculations for Cohort Studies	35
Sample Size Calculations for Case–Control Studies	40
Sample Size Calculations for Case Series	41
Discussion	43
Key Points	45
Further Reading	45
4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies	47
<i>Jeffrey S. Barrett</i>	
Introduction	47
Clinical Pharmacology and Pharmacoepidemiology	48
Basics of Clinical Pharmacology	48
Pharmacokinetics	49
Absorption	49
Volume of Distribution	49
Metabolism	49
Elimination	51
Special Populations	52
Elderly	52
Pediatrics	53
Pregnancy	55
Organ Impairment	55
Drug Interactions	56
Pharmacodynamics	56
Overview	57
Pharmacogenomics	59
Model-Informed Drug Development	59
Conclusion	60
Key Points	60
Further Reading	61
5 When Should One Perform Pharmacoepidemiologic Studies?	62
<i>Brian L. Strom</i>	
Introduction	62
Reasons to Perform Pharmacoepidemiologic Studies	62

Regulatory	63
Marketing	64
Legal	65
Clinical	66
Safety Versus Risk	67
Risk Tolerance	67
Features of the Adverse Outcome	68
Characteristics of the Exposure	68
Perceptions of the Evaluator	69
Conclusion	70
Key Points	70
Further Reading	71

6 Views from Academia, Industry, Regulatory Agencies, and the Legal System 73

Joshua J. Gagne, Jerry Avorn, Nicolle M. Gatto, Jingping Mo, Gerald J. Dal Pan, June Raine, Shinobu Uzu, Aaron S. Kesselheim, and Kerstin N. Vokinger

The View from Academia	73
Introduction	73
The Drug Approval Process	74
Prescribing Practices	75
Evaluation of Patients' Use of Drugs in the Health Care System	76
Assessment of the Quality and Outcomes of Medication Use in Populations	76
Policy Analysis	77
Interventional Pharmacoepidemiology	77
Economic Assessment of Medication-Related Issues	78
The Academic Medical Center	78
Consortia of Academic Medical Center Programs for Pharmacoepidemiologic Research	78
The Future	79
Summary Points for the View from Academia	79
The View from Industry	81
Introduction	81
Regulatory and Industry Focus on Risk Management and Epidemiology	81
Epidemiology in Drug Safety Evaluation	83
Epidemiology in Evaluation of Risk Mitigation Interventions	86
Conclusion	87
Summary Points for the View from Industry	88
The View from Regulatory Agencies	90
Introduction	90
Assessing the Need for Medicines	91
Orphan Drugs	91
Planning Drug Development Programs	92
Pre-approval Review of Clinical Safety Data	93
Planning for Post-approval Studies	94
Monitoring Post-approval Safety	94
Assessing Actual Use Patterns of a Medicine	95
Assessing Impact of Regulatory Actions	95
Advancing the Science of Pharmacoepidemiology	96

Conclusion	97
Summary Points for the View from Regulatory Agencies	97
The View from the Legal System	98
Introduction	98
Tort Law and Product Liability Lawsuits	98
Pharmacoepidemiology and Contract Law	102
Pharmacoepidemiology and Intellectual Property Law	103
Conclusion	105
Summary Points for the View from the Legal System	105
Further Reading	107
The View from Academia	107
The View from Industry	108
The View from Regulatory Agencies	109
The View from the Legal System	110
Contract-Related Issues in Pharmacoepidemiology	110
Patent Law and Pharmacoepidemiology	110

Part II Sources of Pharmacoepidemiology Data 113

7 Postmarketing Spontaneous Pharmacovigilance Reporting Systems 115

Gerald J. Dal Pan, Marie Lindquist, and Kate Gelperin

Introduction	115
Description	116
Adverse Events and Adverse Drug Reactions	116
Overview of Pharmacovigilance Reporting Systems	117
The Concept of Spontaneous AE/ADR Reporting	118
Report Characteristics	119
Social Media	121
National Pharmacovigilance Systems	121
National and International Postmarketing Adverse Event Databases	123
Detecting Signals from a Postmarketing Adverse Event Database	124
Review of Individual Case Safety Reports	126
Reporting Ratios	127
Strengths	128
Signal Detection	128
Opportunity for the Public to Report AEs/ADRs	129
Scope	129
Limitations	129
Quality of Reports	129
Underreporting	130
Non-uniform Temporal Trends in Reporting	130
Particular Applications	131
Case Series and Reporting Rates	131
Data Mining Signals	131
Signals from Developing Countries	131
The Future	132
Key Points	132
Further Reading	134

- 8 Overview of Electronic Databases in Pharmacoepidemiology** 136
Brian L. Strom
Introduction 136
Description 137
 Claims and Other Administrative Databases 137
 Electronic Health Record Databases 138
Strengths 138
Weaknesses 139
Particular Applications 140
The Future 140
Key Points 141
Further Reading 141
- 9 Encounter Databases** 142
Tobias Gerhard, Yola Moride, Anton Pottegård, and Nicole Pratt
Introduction 142
Description 142
 Attributes of Encounter Databases 145
 Selected Encounter Databases 149
Strengths 161
Limitations 162
Particular Applications 163
 Typical Activities Involved in Studies Using Encounter Databases 163
 Deciding Between Individual Encounter Databases 164
The Future 166
Key Points 167
Further Reading 171
US Databases 172
European Databases 172
Canadian Databases 173
Asian Databases 173
- 10 Electronic Health Record Databases** 174
Daniel B. Horton, Harshvinder Bhullar, Francesca Cunningham, Janet Sultana, and Gialuca Trifirò
Introduction 174
Description 174
 Overview of Health Care Systems and Populations 174
 Overview of Databases 181
 Data Collection and Structure 182
 Data Quality: Accuracy and Completeness 183
 Data Access for Researchers 184
Strengths 184
 Population-Based Data, Sample Size, and Length of Follow-up 184
 Validity of Clinical Information 184
 Accuracy of Drug Information 184
 Ability to Access Original Health Records 184
 Linkage to External Patient-Level Data 185

- Limitations 185
 - Incompleteness of Clinical Data 185
 - Incompleteness of Drug Data 185
- The Future 186
- Summary Points for Electronic Health Record Databases 187
- Acknowledgment 187
- Further Readings 189

11 Primary Data Collection for Pharmacoepidemiology 192

- Priscilla Velentgas*
- Introduction 192
 - Research Questions that Require Primary Data 192
 - Hybrid or Enriched Designs 195
- Methods of Primary Data Collection 195
 - Site-Based Data Collection 195
 - Clinician or Site-Reported Outcomes (ClinROs) 195
 - Patient-Generated Data 196
 - Registries as Means of Data Collection 196
 - Biobanks/Specimen Banks 197
 - Guidelines on the Quality of Data Collection 197
- Strengths 197
- Limitations 197
- Particular Applications 198
- Conclusions 199
- Key Points 199
- Further Reading 201

12 How Should One Perform Pharmacoepidemiologic Studies?

- Choosing Among the Available Alternatives 203**
- Brian L. Strom*
- Introduction 203
- Choosing Among the Available Approaches to Pharmacoepidemiologic Studies 203
 - Comparative Characteristics of Pharmacoepidemiologic Data Resources 208
 - Characteristics of Research Questions and their Impact on the Choice of Pharmacoepidemiologic Data Resources 211
- Examples 215
- Conclusion 216
- Key Points 216
- Further Reading 216

Part III Special Issues in Pharmacoepidemiology Methodology 219

13 Validity of Drug and Diagnosis Data in Pharmacoepidemiology 221

- Mary Elizabeth Ritchey, Suzanne L. West, and George Maldonado*
- Introduction 221
- Clinical Problems to be Addressed by Pharmacoepidemiologic Research 221
- Methodological Problems to be Solved by Pharmacoepidemiologic Research 222
 - Indices of Measurement Error Relevant to Pharmacoepidemiologic Research 222

Quantitative Measurement of Validity	222
Quantitative Measurement of Reliability	224
Measurement Error in Pharmacoepidemiologic Research	225
Adjusting Measures of Association for Measurement Error	227
Self-Reported Drug Data from Ad hoc Survey Studies: Recall Accuracy	228
The Influence of Medication Class	228
The Influence of Questionnaire Design	228
The Influence of Patient Population	229
Self-Reported Diagnosis and Hospitalization Data from Ad hoc Studies: Recall Accuracy	230
The Influences of Medical Condition Type	230
The Influences of Timing of Diagnosis and Its Emotional Effects on the Patient	230
The Influence of Patient Population	232
The Influence of Questionnaire Design	232
Currently Available Solutions	233
Following Best Practices for Questionnaire Design	233
Developing a De novo Questionnaire	233
Conducting Validation Studies to Assess Self-Reported Data	235
Considering the Influence of Comparator Selection on Validation Studies	235
Validation of Pharmacoepidemiologic Drug and Diagnosis Data from Electronic Encounter Databases	236
Special Considerations with Drug Data	237
Special Considerations with Diagnosis and Hospitalization Data	237
Special Considerations with Distributed Data Systems	239
Best Practices	239
The Future	242
Key Points	242
Further Reading	243
14 Assessing Causality from Case Reports	246
<i>Bernard Bégaud and Judith K. Jones</i>	
Introduction	246
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	246
The Two Paradigms of Causality Assessment	246
When is Assessing Causation from Cases Reports Useful?	247
Spontaneous Reporting	247
Clinical Trials and Pharmacoepidemiology	248
Clinical Practice and Prescription	248
Reports of Adverse Drug Reactions to Medical Journals	248
Hypothesis Generation and Research	248
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	248
Approaches for Assessing Causation from Individual Cases	249
Expert Judgment/Global Introspection	249
Structured Guidelines and Algorithms	250
Probabilistic Approaches	251
Calibration	253
Choosing the Appropriate Approach	253
The Future	254
Key Points	255
Further Reading	255

15 Molecular Pharmacoepidemiology	257
<i>Christine Y. Lu and Stephen E. Kimmel</i>	
Introduction	257
Definitions and Concepts	258
Genetic Variability	258
Pharmacogenetics and Pharmacogenomics	259
The Interface of Pharmacogenetics and Pharmacogenomics with Molecular Pharmacoepidemiology	259
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	260
Three Ways That Genes Can Affect Drug Response	260
The Interplay of Various Mechanisms	263
The Progression and Clinical Application of Molecular Pharmacoepidemiology	264
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	264
Interactions	266
Type I Error	267
Type II Error	267
Confounding by Population Admixture	268
Currently Available Solutions	269
Identifying Additional Genetic Contributions to Drug Response	269
Interactions	270
Type I Error and Replication	270
Type II Error	271
Confounding by Population Admixture	271
The Future	271
Key Points	273
Further Reading	274
16 Bioethical Issues in Pharmacoepidemiologic Research	276
<i>Laura E. Bothwell, Annika Richterich, and Jeremy Greene</i>	
Introduction	276
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	276
The Emergence, Changing Methods, and Moral Stakes of Pharmacoepidemiology in Twentieth Century North America	276
European Pharmacoepidemiologic Trends and Ethics	280
East Asian Pharmacoepidemiologic Trends and Ethics	282
Methodologic Problems to be Solved by Pharmacoepidemiologic Research	283
Informed Consent	284
Ethics of Surveillance	285
Ethical Benefits of Pharmacoepidemiologic Research for Data Integrity	285
Problems of Conflicts of Interest for Drug Industry Research	286
Currently Available Solutions	286
Good Pharmacoepidemiology and Pharmacovigilance Practices	286
Protections against Conflicts of Interest for Drug Industry-Sponsored Research	288
The Future	289
Acknowledgement	291
Key Points	291
Further Reading	293

17 The Use of Randomized Controlled Trials for Pharmacoepidemiology	294
<i>Samuel M. Lesko, Allen A. Mitchell, and Robert F. Reynolds</i>	
Introduction	294
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	294
Methodological Problems to be Solved by Pharmacoepidemiologic Research	296
Overview of Classic RCTs	296
Limitations of RCTs	298
Currently Available Solutions	298
Large Simple Trials	298
When is an LST Feasible?	301
Logistics of Conducting an LST	302
Analysis	303
Primary Analysis	303
Subgroup Analyses	303
Data Monitoring/Interim Analyses	304
The Future	304
Key Points	305
Further Reading	305
18 Pharmacoeconomics: Economic Evaluation of Pharmaceuticals	307
<i>Kevin A. Schulman</i>	
Introduction	307
Clinical Problems to be Addressed by Pharmacoeconomic Research	307
The Economics of Drug Development	307
Health Economics and Health Care Financing	308
Methodological Problems to be Addressed by Pharmacoeconomic Research	312
Types of Analysis	312
Types of Costs	315
Perspective of Analysis	316
Using Economic Data	317
The Future	320
Acknowledgements	320
Key Points	320
Further Reading	320
19 Patient Engagement and Patient Reported Outcomes	322
<i>Esi M. Morgan and Adam C. Carle</i>	
Introduction	322
Patient Reported Outcomes in Clinical Trials	323
Patient Reported Outcomes in Routine Care	323
Patient Reported Outcomes as Motivation to Develop New Therapeutic Strategies	325
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	326
Ensuring PRO Completion and Results Review	326
PRO Selection, Score Interpretation and Interventions	326
Patient Engagement and Individualized Assessment and Treatment Plans	327
Barriers to Measuring PROs in Clinical Practice and Using PROs to Guide Interventions	327

Methodologic Problems to be Solved by Pharmacoepidemiologic Research	328
Currently Available Solutions	328
Discordance in Perspectives between Patients, Clinicians and Researchers	328
Measuring within Person Change	329
Selection of Patient Reported Outcomes and Implementation into Practice	330
The Future	330
Key Points	331
Further Reading	331
20 The Use of Meta-analysis in Pharmacoepidemiology	334
<i>Brenda J. Crowe, Stephen J.W. Evans, H. Amy Xia, and Jesse A. Berlin</i>	
Introduction	334
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	335
Methodological Problems to be Solved by Pharmacoepidemiologic Research	336
Susceptibility of the Original Studies to Bias	336
Combinability of Studies	336
Publication Bias	337
Bias in the Abstraction of Data	338
Currently Available Solutions	338
Steps Involved in Performing a Meta-analysis	338
Publication Bias	344
Indirect Comparison and Simultaneous Comparison of Treatments Available for Specific Conditions	346
Case Studies of Applications of Meta-analysis	346
The Future	350
Key Points	351
Further Reading	352
21 Studies of Medication Adherence	355
<i>Julie Lauffenburger, Trisha Acri, and Robert Gross</i>	
Introduction	355
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	356
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	357
Currently Available Solutions	357
Analysis Issues in Adherence	362
Use of Adherence Data in Clinical Trials and Comparative Effectiveness Studies	362
Selecting Adherence Intervals	362
Statistical Analysis	363
Time-Varying Nature of Adherence and Trajectory Modeling	364
Prediction of Adherence for Interventions	365
The Future	365
Key Points	365
Further Reading	366
22 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies	368
<i>Sebastian Schneeweiss and Samy Suissa</i>	
Introduction	368

Clinical Problems to be Addressed by Pharmacoepidemiologic Research	368
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	368
Currently Available Solutions	370
Efficient Sampling Designs within a Cohort Study	370
Analytic Approaches for Improved Confounding Control	377
Conclusion	382
Key Points	382
Further Reading	384

Part IV Special Applications and the Future of Pharmacoepidemiology 387

23 Special Applications of Pharmacoepidemiology 389

David Lee, Björn Wettermark, Christine Y. Lu, Stephen B. Soumerai, Robert T. Chen, Sharon-Lise T. Normand, Art Sedrakyan, Danica Marinac-Dabic, Daniel B. Horton, Sonia Hernandez-Diaz, Tamar Lasky, Krista F. Huybrechts, Claudia Manzo, Emil Cochino, Hanna M. Seidling, David W. Bates, Bennett Levitan, Rachael L. DiSantostefano, and Scott Evans

Studies of Drug Utilization 389

Introduction 389

 Clinical Problems to be Addressed by Pharmacoepidemiologic Research 391

 Methodological Problems to be Addressed by Pharmacoepidemiologic Research 392

 Examples of Currently Available Solutions 393

 The Future 396

 Key Points for Studies of Drug Utilization 396

Evaluating and Improving Prescribing 398

 Clinical Problems to be Addressed by Pharmacoepidemiologic Research 398

 Methodological Problems to be Addressed by Pharmacoepidemiologic Research 398

 Examples of Currently Available Solutions 399

 The Future 402

 Key Points for Evaluating and Improving Prescribing 402

Special Methodological Issues in Pharmacoepidemiologic Studies of Vaccine Safety 403

 Clinical Problems to be Addressed by Pharmacoepidemiologic Research 403

 Methodological Problems to be Addressed by Pharmacoepidemiologic Research 404

 Examples of Currently Available Solutions 407

 The Future 408

 Key Points for Special Methodological Issues in Pharmacoepidemiologic Studies of Vaccine Safety 408

Epidemiologic Studies of Implantable Medical Devices 408

 What Is a Medical Device and how Is it Different from a Drug? 409

 Clinical Problems to be Addressed by Medical Device Epidemiologic Research 409

 Methodological Problems to be Solved by Medical Device Epidemiologic Research 410

 Examples of Currently Available Solutions 412

 The Future 415

 Key Points for Epidemiologic Studies of Devices 418

Research on the Effects of Medications in Pregnancy and in Children 418

 Clinical Problems to be Addressed by Pharmacoepidemiologic Research 418

 Methodological Problems to be Solved by Pharmacoepidemiologic Research 419

Examples of Currently Available Solutions	423
The Future	424
Key Points for Research on the Effects of Medications in Pregnancy and in Children	426
Risk Management	427
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	428
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	433
Examples of Currently Available Solutions	434
The Future	434
Key Points for Risk Management	436
The Pharmacoepidemiology of Medication Errors	436
Safety Theory	436
Patient Safety Concepts as Applied to Pharmacoepidemiology	437
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	438
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	441
The Future	442
Key Points for the Pharmacoepidemiology of Medication Errors	442
Benefit–Risk Assessments of Medical Treatments	442
Clinical Problems to be Addressed by Pharmacoepidemiologic Research	443
Methodological Problems to be Addressed by Pharmacoepidemiologic Research	443
Examples of Currently Available Solutions	444
The Future	451
Key Points for Benefit–Risk Assessments of Medical Treatments	454
Further Reading	454
24 The Future of Pharmacoepidemiology	464
<i>Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy</i>	
Introduction	464
The View from Academia	465
Scientific Developments	465
Funding	469
Personnel	470
The View from Industry	471
The View from Regulatory Agencies	472
The View from the Law	473
Conclusion	473
Key Points	473
Further Reading	474
Appendix A – Sample Size Tables	475
Appendix B – Glossary	493
Index	505